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Case presentation
A 25-year-old woman in labor was admitted to the Yale-New Haven
Hospital. Ten years earlier, 3+ proteinuna was noted on a routine
physical examination. At that time there were no abnormal physical
findings, including no evidence of edema. Her blood pressure was 115/
70 mm Hg (sitting). The hematocrit was 40%; BUN, 11 mg/dl; and
serum creatinine, 0.6 mg/dl. Urinalysis disclosed 10 to 15 red blood cells
and 6 to 8 white blood cells per high-power field and an occasional
granular cast. An antinuclear antibody study was negative; C3 was 30
mg/dl (normal, 65—120 mg/dl); total serum protein, 4.5 g/dl; and serum
albumin, 2.5 g/dl. A urine culture was negative. An intravenous
pyelogram was reported as normal. Percutaneous renal biopsy demon-
strated mesangiocapillary glomerulonephritis.
Approximately 5 years before admission, the patient noted intermit-
tent dependent edema, and furosemide was prescribed. Her blood
pressure at that time was in the range of 150/100 mm Hg, and
antihypertensive treatment was instituted with propranolol and hydral-
azine. Two years earlier an obstetrician whom she had consulted about
the possibility of pregnancy referred her to the Yale-New Haven
Hospital. At that time her blood pressure was 130/90 mm Hg and there
were no abnormal physical findings. She reported swelling in her lower
extremities, below mid-calf, at approximately 2- to 3-week intervals;
the edema promptly subsided after a single dose of furosemide, 40 mg.
She was taking propranolol, 40 mg, and hydralazine, 25 mg, both twice
daily on a regular basis. Pertinent laboratory findings included: hemato-
crit, 38%; BUN, 12 mg/dI; serum creatinine, 0.9 mg/dl; serum albumin,
2.5 gIdl; urine protein, 4.0 g/24 hr; and creatinine clearance, 115 mllmin.
She and her husband were advised that pregnancy was likely to be
complicated by increased edema formation and that control of hyper-
tension might become more difficult. She also was told that there was a
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good chance, however, for her carrying the pregnancy to term, although
gestation would require close medical supervision, In addition, because
of the progressive nature of her glomerulopathy, she was advised to
attempt conception, if she chose to do so at all, while her renal function
was normal rather than at a later time.
Throughout the pregnancy, propranolol and hydralazine were contin-
ued in the same doses as before conception; blood pressure was
recorded twice daily at home and was maintained in the range of 120—
150/80—95 mm Hg. A low-sodium diet was instituted in the first
trimester, 1500 mg/24 hr, in an effort to blunt the expected rate of edema
formation. At approximately 20 weeks gestation, she developed edema
in her legs; the edema partially responded to intermittent doses of
furosemide, 160 mg. The diuretic was used to reduce edema to a level
that decreased discomfort, but no attempt was made to eliminate the
edema entirely. In the third trimester, edema was more refractory to
diuretics; bed rest at home was prescribed and she was encouraged to
lie on her side. Laboratory studies demonstrated: hematocrit, 32%;
serum creatinine, 1.2 mgldl; serum albumin, 1.5 g/dl; urine protein, 12 g/
24 hr. Physical examination and ultrasound examination revealed
normal fetal growth, and the patient experienced spontaneous labor in
the 38th week of gestation; she delivered per vagina a 3100 g male
infant. At delivery the Apgar score was 9 and no developmental
abnormalities were noted.
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DR. JOHN P. HAYSLETT (Chief, Section of Nephrology, and
Professor of Medicine, Yale University School of Medicine,
New Haven, Connecticut): This patient illustrates many of the
issues that confront the physician managing a woman with renal
disease who wishes to become or is already pregnant. The
patient usually wants to know whether pregnancy will influence
the natural course of her underlying renal disease and/or
whether gestation will cause new complications. Certainly she
wishes to know her chances for delivering a healthy baby. The
physician may be confronted with the problem of diagnosing the
cause of renal dysfunction during pregnancy and selecting a
treatment regimen most likely to promote the viability and
development of the fetus. I should like to discuss salient
information on the physiologic alterations that occur during
normal pregnancy, because these changes have a direct bearing
on the detection and evaluation of renal disease during pregnan-
cy. In addition, I will review new information related to the
effect of pregnancy on the course of renal disease and the
effects of renal disease on pregnancy and fetal outcome.
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Women positioned in lateral
recumbency
Fig. 1. Early increment in glomerular filtration
rate and effective renal plasma flow is
position dependent and is sustained if subjects
are studied in lateral recumbency. (Adapted
from Peppig L: Clinical aspects of renal
disease in pregnancy. Med Hyg 27:181—192,
1969, in Lindheimer MD, Katz Al: Kidney
Function and Disease in Pregnancy.
Philadelphia, Lea & Febiger, 1977.)
Renal function and extracellular volume status
during pregnancy
Normal pregnancy is characterized by a gradual, cumulative
retention of 500 to 900 mEq of sodium and 6 to 8 liters of water,
which are distributed between the maternal extracellular fluid
and the fetoplacental unit. Plasma volume rises by 30% to 45%:
this change in volume status, marked in the second trimester, is
sustained to term. Despite the increase in extracellular volume,
blood pressure falls owing to a decrease in peripheral vascular
resistance.
Changes in renal function during gestation occur against this
background of alterations in extracellular volume. The glomeru-
Ear filtration rate (GFR) begins to rise soon after conception and
achieves a level 30% to 50% above control by the twelfth week
of gestation. Similar changes occur in renal plasma flow. The
elevation in GFR is sustained until term, after which the GFR
rapidly falls to nongravid levels [1, 2], as shown in Figure 1.
This figure also shows that GFR and renal plasma flow are
markedly influenced by position in late pregnancy. When a
pregnant woman changes from lying on her side to an upright or
supine position, renal plasma flow and GFR immediately de-
crease. Unless GFR is measured in a lateral decubitus position,
the intrinsic level will be underestimated. During pregnancy,
plasma levels of BUN and serum creatinine are reduced below
nonpregnant values because of the increase in filtered load and
the dilutional effect of expansion of the extracellular fluid [3]. It
has been suggested that values of blood urea nitrogen above 13
mg/dl and serum creatinine levels above 0.8 mg/dl should alert
the physician to the possibility of renal insufficiency [41.
The demonstration that GFR increases during the first and
second weeks of pregnancy in the rat has prompted studies into
the factors responsible for these changes. In the rat, gestation
lasts 21 to 22 days. Recent studies have shown that GFR is
increased by day 5 or 6 and that it rises still further by day 10 or
11 [5]. This change in GFR is associated not only with the
increase in extracellular fluid volume that I mentioned, but also
with an approximately 10% increase in the length of the
proximal tubule [6], Micropuncture studies have indicated that
single-nephron GFR correlates with glomerular plasma flow
rate, and not with other determinants of ultrafiltration [7].
Similar changes in renal function and volume status have been
observed in pseudopregnancy, that is, in studies in which
female rats were mated with vasectomized males [8]. There-
fore, it is unlikely that the fetoplacental unit is required for
pregnancy-induced changes in renal function. Further studies
suggest that neither progesterone nor estrogen are causative
factors [8], although prolactin has not been excluded from
contributing to changes in renal function and structure during
pregnancy [9].
The retention of sodium by the gravid female appears to
represent a normal physiologic response mediated by factors
controlling extracellular volume status. Clinical studies have
demonstrated similar responses both to acute volume expan-
sion with sodium salts and to acute restriction in sodium intake
during gestation and in nonpregnant women [10, 11]. On the
basis of these observations, there is no rationale for reducing
dietary sodium intake in normal pregnancy.
In addition to changes in GFR and renal handling of sodium,
plasma osmolality regularly falls to about 270 mOsm/liter in
normal pregnancy. In an elegant study in the rat, Dun, Sta-
moutsos, and Lindheimer showed that this gestation-induced
effect on osmolality is secondary to a resetting of the osmostat
[12]. Plasma bicarbonate also falls during pregnancy from 26 to
28 mEq/liter to approximately 20 mEq/liter, owing to a mild,
progesterone-induced respiratory alkalosis.
Urinary protein excretion is not increased in normal pregnan-
cy; therefore, daily excretion rates above 200 mg should be
regarded as abnormal. The urinary excretion of glucose and
amino acids, however, can increase in the absence of an
increase in plasma levels, apparently because of a change in
binding affinity of proximal tubular cells or because of a
saturation of maximal transport capacity for these substances
[13].
An understanding of these physiologic changes in normal
pregnancy has important clinical implications, because the
detection of renal disease and the evaluation of patients with
established renal disease must take into account the expected
physiologic alterations in renal function. An evaluation of GFR,
for example, should compare observed measurements with
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found in the nonpregnant state. It is of interest that a recent
analysis of 33 women with various types of primary renal
disease and a moderate decrease in GFR before pregnancy
disclosed a similar increment in GFR and effective renal plasma
flow as that observed in normal gravidas [14].
Diagnosis of renal dysfunction during pregnancy
An important clinical question in many patients with protein-
uria during pregnancy is whether the renal abnormality is a
manifestation of preeclampsia or whether it results from anoth-
er cause of renal disease. Because preeclampsia does not occur
before the twentieth week of gestation (except in hydatidiform
mole or multiple gestational pregnancies), the differential diag-
nosis is simplified if signs of renal disease were present before
conception or in the first trimester. When proteinuria is first
discovered after the twentieth week of pregnancy, however,
one often has difficulty distinguishing between underlying renal
disease and preeclampsia, because the clinical features—pro-
teinuria, hypertension, edema, and renal insufficiency—occur
in both settings.
Fisher and associates have provided information about the
relative incidence of the causes of proteinuria and hypertension
during gestation in a series of 176 patients who underwent renal
biopsy within 6 days of delivery [15]. Renal biopsy was an
important feature of this analysis, because glomerular capillary
endotheliosis is thought to be specific for preeclampsia and is
invariably present, even in mild cases [16]. Among primigravi-
das, the incidence of preeclampsia was 83%; intrinsic renal
disease (excluding preeclampsia), 12%; and hypertensive gb-
merulosclerosis, 5%. In multiparous patients, in contrast, pre-
eclampsia occurred in only 38% of patients, whereas intrinsic
renal disease accounted for 26%, and hypertensive renal dis-
ease for 26%. Preeclampsia was superimposed on one of the
other renal parenchymal lesions in 10% of patients. Prior to
delivery, preeclampsia was the primary diagnosis in nearly all
patients. This analysis demonstrates that the diagnosis of
preeclampsia cannot be made with certainty on clinical grounds
alone, particularly in multiparous patients and in those with
coexistent renal disease.
Effects of pregnancy on renal disease
and of renal disease on the outcome of pregnancy
Patients whose renal function is sufficiently impaired to raise
serum creatinine above 2 to 3 mg!dl are usually infertile.
Therefore data bearing on the effect of pregnancy on the course
of underlying renal disease principally involves patients with
only mild to moderate reductions in renal function. Although a
few reports suggest that pregnancy leads to progressive deterio-
ration of renal function [17, 18], the majority of investigations
indicate that pregnancy does not influence the natural course of
renal disease, if renal function is relatively well preserved and
hypertension is absent at conception [14, 19, 20].
Katz and associates at three centers provided new insights
into this relationship in a combined prospective and retrospec-
tive study of 121 pregnancies (between 1959 and 1979) in 89
women with renal disease [14]. The women were included in the
study only if renal tissue was available for examination and if
pregnancy continued at least through the first trimester. Their
clinical course was studied through subsequent pregnancies, if
any, and for periods of varying length. Pregnancies ending in
therapeutic abortion were not included. These women had a
variety of renal diseases: chronic diffuse gbomerulonephritis in
26, focal glomerulonephritis in 12, membranous nephropathy in
7, and interstitial nephritis in 21. Prior to conception, hyperten-
sion was present in 20%, but it was mild in most. Proteinuria
was found in one-third of women, but exceeded 1 g/24 hr in less
than one-half, and in all patients the serum creatinine level did
not exceed 1.4 mgldl.
During the course of pregnancy, shown in Figure 2, hyperten-
sion was noted in 23% of gestations, but in one-half blood
pressure was elevated before conception. Renal function de-
creased in 16% of all pregnancies in this series, most often in
women with diffuse glomerulonephritis (11 of 19). In general,
the reduction in renal function was mild to moderate, and renal
function returned to pregestational levels after delivery. In 2
cases, marked deterioration of renal function was due to acute
tubular necrosis, and in 3 women pregnancy seemed to occur in
the downhill phase of the disease, which eventually progressed
to renal failure. Increased proteinuria was the most common
adverse renal effect of gestation, occurring in 47% of pregnan-
cies. In 39 pregnancies, the rate of protein excretion exceeded 3
g124 hr. During follow-up, which ranged from 3 months to 23
years, and which averaged 62 months, the changes in renal
function and blood pressure observed during pregnancy usually
remitted. Moderately severe hypertension was present in only
one patient; 7 others had mild hypertension, but 4 of them were
hypertensive before pregnancy. Although abnormal protein
excretion was present in 23 women at the end of follow-up, it
exceeded 3.0 g/day in only 5 patients. Renal function was
reduced in 10 patients at the end of follow-up. One-half of these
patients progressed to end-stage renal failure; in the remaining 5
patients, shown in Figure 2, renal function was only moderately
reduced (serum creatinine s 1.7 mgldl). Because the onset of
end-stage renal failure varied between several weeks and more
than 8 years after delivery, the authors concluded that there
was no evidence that pregnancy accelerated the rate of progres-
sion of the underlying renal disease.
Other workers also have reported an increase in protein
excretion during pregnancy, often to nephrotic levels [20—22].
As expected, this complication usually occurs in patients with
glomerulopathies, not tubulointerstitial diseases. The rate of
protein excretion falls in most subjects to preconception levels
following delivery. Heavy proteinuria and nephrotic syndrome
also can occur in preeclampsia, and therefore the magnitude of
proteinuria does not distinguish patients with underlying renal
disease from those with preeclampsia. In a recent report of 23
women with biopsy-proven preeclampsia and nephrotic syn-
drome, protein excretion at follow-up (average, 36 months) was
mildly abnormal in only 2 patients, and only one patient with
polycystic kidney disease had an elevated serum creatinine
level [23].
The outlook for the fetus in women who become pregnant
despite the presence of renal disease seems favorable as long as
significant hypertension is absent and renal function is not
severely reduced. In an analysis of S series of pregnancies in
women with renal disease, Ferris reported no maternal deaths
and a fetal survival rate of 93% in 176 normotensive mothers
[24]. In contrast, a fetal survival rate of only 55% was found in
women with renal disease and hypertension. In the series of 121
pregnancies reported by Katz and associates, the fetal survival
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Fig. 2. Course of renal disease in 89 women
during gestation and the puerperium (3 bars
on the left) and in 80 women followed after
pregnancy (4 bars on the right). Numbers
within bars are individual pregnancies (on the
left) and individual women (on the right). BP
refers to blood pressure; ESRD refers to end-
stage renal disease; FX refers to function.
(Reproduced with permission from
LINDHEIMER MD, KATZ Al: Maternal and
fetal prognosis in women with chronic renal
disease, in Fetal Growth Retardation, edited
by VANASSCHE FA, ROBERTSON WB,
Edinburgh, Churchill Livingstone, 1981,
p 146.)
rate was 94% [141. It should be noted, however, that 20% of
deliveries were preterm and that 27 of 111 infants whose birth
weights were known (24% of all live births) were small for
gestational age. These data therefore indicate that the likelihood
of prenatal survival is only slightly reduced by the presence of
primary renal disease with normal to moderately reduced renal
function but that the incidence of retarded fetal growth is
increased. In contrast, the relatively few patients with ad-
vanced renal failure who do become pregnant experience a live
birth rate of only about 20% to 50% and a high frequency of fetal
growth retardation [25].
Regarding women who have systemic diseases affecting the
kidney, there is a paucity of data except for those with diabetes
mellitus and systemic lupus erythematosus (SLE). Sims report-
ed that pregnancy did not worsen renal function in 8 patients
with diabetic glomeruloscierosis (and normal renal function
prior to pregnancy), even in women with severe, long-standing
diabetes mellitus [26]. Kitzmiller and associates reported their
experience with 26 women with diabetic nephropathy who
attained 24 weeks gestation [27]. Eight of these women had a
creatinine clearance less than 70 mI/mm (average, 43 mI/mm)
when they conceived; in the group as a whole, renal function
generally remained stable throughout pregnancy and to the end
of follow-up (9 to 35 months later). Proteinuria increased
dramatically in the majority of patients, however, exceeding 6
g/day in 58% of patients. As in patients with primary renal
disease, protein excretion fell to pregestational levels following
delivery. Perinatal survival was 89% in this series of diabetic
patients but, as expected, the rate of fetal growth retardation
was high, 20.8%; macrosomia was observed in 12.5%.
Restrospective analyses of large series of women with SLE
disclose that pregnancy can induce the disease in some patients
with a predisposition for SLE, and it can exacerbate the disease
in some patients with established SLE. In most studies of 20 or
more patients with both pregnancy and SLE, the disease first
appeared during gestation in about 10% of patients [28]. In
addition, the rate of relapse and exacerbations of clinical
activity in patients with an established diagnosis prior to
conception appears to increase during pregnancy and postpar-
tum. A recent report by Hayslett and Lynn, using data from 13
nephrology groups in the United States and Canada, analyzed
the clinical course of SLE during 65 pregnancies in 47 patients
with lupus nephropathy [291. A renal biopsy specimen was
available in 77% of the patients, and on the basis of the selection
criteria it seemed likely that bias in selection favored inclusion
of those whose lupus nephropathy was more severe. This
analysis indicated that signs of extrarenal activity and/or renal
disease before conception correlated with clinical activity dur-
ing pregnancy and postpartum in 43 women (56 pregnancies)
whose SLE was manifest before pregnancy. Of 31 pregnancies
characterized by complete clinical remission (including signs of
renal disease) for at least 6 months before conception, remis-
sion persisted throughout pregnancy in two-thirds, whereas in
one-third the pregnancy was complicated by clinical relapse,
including 3 patients with nephrotic syndrome and 3 with moder-
ately severe renal insufficiency. In all instances, however, a
complete or partial remission occurred after delivery and,
excluding therapeutic abortions, the incidence of live births was
88%. Of 25 pregnancies associated with preceding signs of
disease activity, including either extrarenal or renal involve-
ment, SLE activity was unchanged or improved in 52% but
worsened in 48%. Exacerbations were more severe in this
group, and increased disease activity persisted postpartum in
one-fourth of patients. The live birth rate in this cohort was
64%. A history of severe systemic disease or renal disease in
the remote past did not correlate with the course or outcome of
pregnancy. The live birth rate did, however, correlate with the
level of renal function during pregnancy; the rate of live births
was reduced 50% in 10 noninterrupted pregnancies in patients
with a serum creatinine of 1.5 mg/dl or more. The results of this
analysis of SLE and pregnancy have been corroborated by
other recent reports (see Ref. 28 for review).
Nephrotic syndrome in pregnancy
The nephrotic syndrome is a common problem among preg-
nant women with glomerulopathies due to primary renal disease
or systemic disease; in such patients, fluid retention often
worsens during late pregnancy, often coexisting with a further
reduction in plasma albumin concentration. In addition, reten-
tion of fluid can aggravate hypertension. Nevertheless, in most
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series more than 90% of patients with normal or only slightly
impaired renal function give birth to live babies. Although a low
birth weight was said to correlate with a low plasma albumin
level in one study [21], this finding has not been confirmed in
others [201.
In summary, the current data suggest that pregnancy does not
accelerate the course of renal disease, except in patients with
SLE in whom the systemic disease may become exacerbated
during pregnancy. In most reports the live birth rate is approxi-
mately 90% in patients who have neither severe renal insuffi-
ciency nor severe hypertension at conception. In the presence
of either of these features, the likelihood of a successful
outcome is reduced substantially. Women with renal disease
who become pregnant, however, are at higher risk for develop-
ing nephrotic syndrome and have a higher incidence of preterm
and small-for-gestational-age babies.
Management of pregnant patients with renal disease
Pregnant women with renal disease are in a high-risk category
and preferably should be managed in centers with facilities for
accurate and close fetal monitoring and with personnel experi-
enced in treating the complications encountered in patients with
renal disease. Because pregnancy does not adversely affect
renal disease, the primary aim of management is to maintain
pregnancy until fetal maturity is assured by sensitive monitor-
ing techniques.
Hypertension is a common complication of renal insufficien-
cy and often is exacerbated by pregnancy; therefore hyperten-
sion should be anticipated, and if it occurs it should be treated
effectively. I will discuss the use of antihypertensive agents in
pregnancy momentarily. Generally, hematocrit values should
be maintained above 25%, and intermittent transfusions should
be given if necessary. It is our view that glucocorticoids and
cytotoxic agents, including azathioprine and cyclophospha-
mide, should be employed in pregnant patients with active
SLE, systemic vasculitis, and similar diseases. Because clinical
studies to date have not found that these agents induce develop-
mental abnormalities in the fetus, the threat of the underlying
disease to maternal health and fetal viability is regarded as
being greater than the potential risk of fetal drug toxicity. The
management of patients with diabetic glomerulosclerosis re-
quires special efforts to maintain blood glucose levels within a
normal range, as in pregnant diabetic patients in general. The
principles and practical aspects of prenatal care of this group of
patients are described elsewhere [30].
Although renal biopsy has been performed successfully dur-
ing pregnancy and has important implications in establishing the
cause and severity of renal injury, limited experience with this
technique during gestation in most centers should, in our
judgment, preclude its use until after delivery. If the diagnosis
of preeclampsia is an important diagnostic consideration, renal
biopsy should be performed within approximately 7 days after
delivery, because the finding of glomerular capillary endothelio-
sis is thought to be pathognomonic for preeclampsia, and the
abnormality resolves soon after delivery [16].
The use of diuretics for control of hypertension and edema in
pregnant patients is controversial. Concern exists that these
agents may reduce placental blood flow and hence threaten fetal
survival. Reports of fetal complications related to the use of
some antihypertensive agents also have generated concern.
Much of the concern about diuretics is based on studies by Gant
and colleagues, who reported a reduced metabolic clearance
rate of dehydroepiandrosterone sulfate (DHEA) in patients
treated with either thiazides or furosemide [31]. Since approxi-
mately 40% to 50% of the total metabolic clearance rate of
DHEA reflects placental conversion of the substance to estradi-
ol, a fall in its metabolic clearance rate is thought to represent a
decrement in uterine blood flow and placental metabolic com-
petence. It is of interest, however, that in a randomized,
double-blind study of early and continuous use of 50 mg of
hydrochlorothiazide in 1030 obstetric patients, no significant
difference in birth weight was found between control and
thiazide groups [32]. Until the question of whether diuretic
agents reduce placental blood flow is resolved, these drugs
should be used judiciously in selected patients. In addition to
diuretics, beta-adrenergic antagonists, such as propranolol,
have been reported to cause intrauterine growth retardation and
neonatal hypoglycemia and bradycardia [for review, see Ref.
33]. Other antihypertensive agents, including guanethidine,
rauwolfia alkaloids, clonidine, captopril [34], and diazoxide,
have not been recommended either because of maternal and
fetal complications, or because of inadequate evaluation in
pregnant patients.
There is no generally accepted technique for treating hyper-
tension in the pregnant patient. Some authorities recommend
continuing the same regimen during pregnancy that has proved
effective prior to conception, including the use of thiazide
diuretics [33]. Methyldopa and hydralazine are preferred in
patients who become hypertensive after conception because
extensive experience during pregnancy has failed to indicate
significant maternal or fetal complications. Thiazide diuretics
should be added to the regimen only after methyldopa and
hydralazine have proved inadequate. Criteria for initiating
treatment recently has shifted to higher diastolic levels because
of increasing concern about adverse effects of drugs on the
fetus. Feitelson and Lindheimer define moderate hypertension
in pregnancy as a diastolic blood pressure greater than 100 mm
Hg in the second trimester or 110 mm Hg in the third trimester
[35]. We now believe that therapeutic measures should be
introduced to prevent the level of diastolic blood pressure from
exceeding 95 mm Hg at any time during pregnancy.
In patients with the nephrotic syndrome, we recommend that
sodium restriction be initiated before edema develops. Because
pregnant women can absorb sodium avidly, negative sodium
balance should not occur. In most patients with nephrotic
syndrome, sodium restriction and frequent periods of bed rest
prevent anasarca. When this regime has proved inadequate, we
have employed diuretics, including furosemide, on an intermit-
tent basis to avoid excessive edema formation. The goal of
therapy is maintaining the level of edema at a tolerable level by
inducing weight decrements of 2 to 3 lbs with each course of
treatment; the regimen does not attempt to eliminate all edema.
Dialysis and renal transplantation
Both peritoneal dialysis and hemodialysis have been used
successfully in pregnant patients with acute and chronic renal
failure. Most reports of hemodialysis, however, involve single
case reports or small series. Nissenson reviewed the accumulat-
ed literature consisting of 20 pregnant women, and reported that
fetal survival was approximately 50%, with a high incidence of
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preterm delivery [36]. He reported that hypotension and vaginal
bleeding were frequent complications in patients treated with
hemodialysis, and that premature contractions or labor often
occurred during or immediately after treatment. There is no
evidence that early hemodialysis treatment in this group of
patients promotes increased fetal survival. Also, no substantial
experience with peritoneal dialysis has been reported, and I am
unable to comment about its potential usefulness. On the basis
of available data, I believe that dialysis should be instituted
according to the same criteria used for nonpregnant individuals.
There is no evidence that the potential benefits of earlier
treatment outweigh the risk of dialysis-induced complications.
A substantial number of women with renal transplants have
successfully conceived and sustained pregnancies. Penn, Ma-
kowski, and Harris reviewed the course of 56 pregnancies in 37
women; of the 44 live-born neonates, 70% were normal and 30%
had one or more complications, including respiratory distress
and seizures [37]. Only 6 of these 44 neonates were small for
gestational age, but 4 had congenital abnormalities. Labor and
delivery were uncomplicated. It should be noted that approxi-
mately 50% of the patients who had impaired graft function at
conception developed evidence of preeclampsia during preg-
nancy; preeclampsia also occurred in 5 patients who had normal
graft function. The European Dialysis and Transplantation
Association reported 110 live deliveries in 97 transplant pa-
tients; the total number of conceptions and the level of basal
renal function were not reported [38]. Twenty-one patients had
evidence of a decline in renal function in association with
pregnancy, and the incidence of small-for-gestational-age in-
fants and preterm deliveries was increased above the rate in
normal subjects.
I have summarized the salient physiologic changes in renal
function and volume status that occur in pregnancy, and
pertinent data on the course of pregnancy in women with renal
disease. It is my view that the patient and spouse ultimately
have responsibility for deciding whether to conceive or to
continue a pregnancy. The physician's role is to provide data on
the risks and chances for a successful outcome, to interpret
these data for the patient and her spouse, and to provide close
supervision for women who decide to conceive or complete a
pregnancy. The goal of treatment is to prevent maternal compli-
cations and maximize the chance of a live birth.
Questions and answers
DR. JOHN T. HARRINGTON: We know that GFR increases
markedly immediately after conception in rats. When does this
occur in humans?
DR. HAYSLETT: The rise in GFR occurs very soon after
conception. Davidson has shown that the GFR is significantly
increased by the eighth week of gestation, and that it reaches
maximum levels within another 4 weeks [1].
DR. HARRINGTON: You mentioned that proximal tubule
length increases by 10% in the pregnant rat. Does that 10%
increase in length translate to an increase in volume of the
proximal nephron sufficient to account for reabsorption of the
increase in sodium load, or does the increase in sodium
reabsorption require changes in distal tubular function as well?
DR. HAYSLETT: Micropuncture studies in the rat have shown
that fractional reabsorption of sodium in the proximal convolu-
tion does not differ at 6 and 12 days of gestation between
pregnant and control animals, despite the increase in filtered
load [39]. I am unaware of studies designed to examine your
specific question, that is, is the apparent luminal surface area
increased to match the change in filtered load of sodium?
The change in renal growth in pregnancy is reminiscent of
compensatory growth after loss of renal mass. Studies from my
laboratory several years ago demonstrated that the luminal
volume of the proximal tubule paralleled the compensatory rise
in glomerular filtration rate after uninephrectomy [40]. Structur-
al changes included a 35% increase in length and a 17% increase
in luminal diameter. Under these conditions there was a rise in
absolute sodium absorption in the proximal tubule in the
absence of a change in fractional reabsorption.
DR. JEROME P. KASSIRER: I agree with your view that the
husband and wife must take substantial responsibility for decid-
ing whether to have a child, and that the physician's role is to
provide data and advice, Except for patients with active lupus,
are there any circumstances in which you strongly advise
against attempting pregnancy? Are there any circumstances in
which the danger is sufficient to justify recommending thera-
peutic abortion?
DR. HAYSLETT: I think patients should be discouraged from
becoming pregnant or continuing pregnancy in the early stages
of gestation if a high likelihood exists that maternal health will
be impaired if the pregnancy is carried to term, and if there is a
reduced outlook for a live birth. These patients generally are
those with severe hypertension, especially if they have a poor
response to drug therapy. In the third trimester, deterioration of
renal function due to presumed preeclampsia is an indication for
termination of pregnancy.
Also, I believe that patients and their spouses should consid-
er their responsibilities towards child rearing as well as child
bearing. This issue is especially important in patients with
congenital renal disease and when rapid progression to end-
stage renal failure seems certain. For patients with a congenital
lesion, such as polycystic kidney disease, counseling by a
clinical geneticist is often helpful. In the final analysis, howev-
er, the patient and spouse have the responsibility for determin-
ing the course of the pregnancy, and I believe that the physician
should support their decision.
DR. KASSIRER: Several factors have changed my approach to
these patients in the past 10 to 15 years. First, the risks to the
mother and fetus in the patient with renal disease are less than
earlier estimates led us to believe. Second, patients are more
willing to take risks because adoption is more difficult now that
fewer babies are available. Third, we are substantially less
paternalistic now than before for a number of appropriate
reasons. Do you find it easier or more difficult now to counsel
such families? Are we justified in discouraging patients from
becoming pregnant?
DR. HAYSLETT: As you know, most patients today expect to
share in decisions involving diagnostic and therapeutic plans. I
don't think that issues related to pregnancy are different from
those in other areas of medicine, and I believe that the quality of
patient care is enhanced if the patient-doctor relationship is
viewed as one in which both parties assume an active role.
Because I have always tried to practice medicine along these
lines, I have not experienced any personal difficulty with the
recent tendency of patients to want more information and to
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participate in a more active manner in decisions that affect their
health care.
Regarding the question of whether we are justified in discour-
aging patients from becoming pregnant, I don't think that, in
principle, this issue is any different than our efforts to encour-
age patients to avoid other factors that can adversely affect their
health, such as cigarettes, alcohol, or emotionally stressful
circumstances. I assume that whenever a physician provides
advice that touches on an important area of life, such as having
children or the patient's occupation, the doctor speaks from an
informed position and is free of personal bias.
DR. ANDREW S. LEVEY (Division of Nephrology, NEMC):
What causes the increase in proteinuria during pregnancy in
women with preexisting renal disease?
DR. HAYSLETT: There is no answer to your question at
present. It seems likely, however, that the increased filtered
load of protein, which is due to the rise in GFR, plays an
important role in the increase in proteinuria that is regularly
observed in pregnant proteinuric patients. Recent work sug-
gests that the reabsorption of albumin by the proximal tubule
might approach the maximum transport rate under control
conditions; therefore, changes in the filtered load in patients
with preexisting proteinuria would be expected to influence
protein excretion rates.
Da. LEVEY: If that were the only explanation, one would
expect the rise in urinary protein excretion to parallel the rise in
glomerular filtration rate during pregnancy. Yet the data you
reported for women with diabetic nephropathy indicate that the
magnitude of proteinuria does not increase until the third
trimester, although glomerular filtration rate increases during
the first trimester.
Dg. HAYSLETT: I agree with your suggestion that the further
rise in protein excretion in the last trimester of pregnancy
implies that the mechanism for the change in protein excretion
is multifactorial.
DR. SUSAN Hou (Division of Nephrology, NEMC): Since you
believe that pregnancy does not hasten the decline in renal
function in women with renal disease, if a woman wanted to
become pregnant but was infertile because of renal insufficien-
cy, would you be willing to try to induce fertility with drugs?
DR. HAYSLETT: I haven't been confronted with that problem,
although if I were I probably would apply the same principles as
I would with a woman who already had the capacity to
conceive. I would discuss the likelihood of her having a
successful pregnancy and the potential risk to her if she became
pregnant. As I mentioned before, I think couples who are likely
to be confronted with major health problems also should
consider the question of their ability to raise a child under the
conditions of increased physical and emotional burdens.
DR. KASSIRER: Dr. Hou, does clomiphene work in patients
with moderate to advanced renal disease? Second, how does
renal insufficiency prevent a patient from becoming pregnant?
DR. Hou: Clomid has been given to only a few patients
whose serum creatinine levels approximate 2 mg!dl, so we do
not know the answer to your first question. The mechanism for
infertility in renal failure is not known. Although hyperprolac-
tinemia is common in dialysis patients, we have found elevated
prolactin levels in only one-fourth of patients with serum
creatinines between 2 and 8 mg!dl (unpublished observations).
DR. JERRY MCCAULEY (Nephrology Division, NEMC): As
you pointed out, pregnant women are slightly hypoosmolar. Is
this because of alterations in ADH secretion or metabolism, or
because of a resetting of the osmostat? Is this effect centrally
mediated?
DR. HAYSLETT: Rat studies performed in Marshall Lind-
heimer's laboratory showed that the fall in serum osmolality
during pregnancy was centrally mediated. The osmostat re-
sponds normally to small changes in osmolality, but at a lower
absolute value than in the nonpregnant state.
DR. MARTIN GELMAN (Renal Division, St. Elizabeth's Hospi-
tal, Boston): Are data on the natural history of proteinuria and
the glomerular lesion in preeclampsia well documented?
DR. HAYSLETT: Most workers agree that glomerular endothe-
liosis is specific for preeclampsia. The question of whether the
lesion is present in all patients with preeclampsia, including
those with mild clinical disease, remains unsettled. Sheehan
recently reviewed this topic [16].
DR. GELMAN: You mentioned that the glomerular endothelio-
sis that occurs with preeclampsia resolves shortly after deliv-
ery. Do you ever biopsy patients with postpartum proteinuria?
If so, how long after delivery do you allow for the proteinuria to
clear before proceeding with biopsy?
DR. HAYSLETT: It is generally assumed that the clinical
manifestations of preeclampsia completely resolve within 6
weeks after delivery. The persistence of proteinuria beyond 6
weeks postpartum strongly suggests another cause for the
proteinuria. In attempting to distinguish between preeclampsia
and a primary glomerulopathy, we usually wait 6 weeks post-
partum. If proteinuria disappears, we assume the cause was
preeclampsia. If proteinuria persists, we evaluate the patient
further, including renal biopsy, using the same criteria for study
that we usually apply to nonpregnant individuals.
DR. WARREN GooRNo (Staff Nephrologist, Emerson Hospi-
tal, Concord, Mass.): What is the incidence of congenital
anomalies in children born to immunosuppressed women who
have received a renal allograft?
DR. HAYSLETT: Penn, Makowski, and Harris at the Universi-
ty of Colorado compiled data on children born to women with
renal allografts [37]. Fifty-six pregnancies resulted in 44 live
births and 4 congenital abnormalities. The authors concluded
that the incidence of congenital abnormalities was no greater
than that expected in a normal population. But I regard this
question as unsettled at present because of the relatively small
number of patients studied.
DR. Hou: First, are you aware of any experience with
pregnancy in renal transplant patients treated with cyclosporin?
Second, do you know of any long-term follow-up data on
children of mothers treated with azathioprine? Do these off-
spring have a higher-than-average risk of childhood
malignancy?
DR. HAYSLETT: I know of no clinical experience in which
pregnant women have been treated with cyclosporin, nor am I
aware of long-term studies of children whose mothers were
treated with immunosuppressive agents during pregnancy. Ob-
viously these are important questions, and information on these
issues is critical if we are to discuss the risks of pregnancy in
women treated with these agents during pregnancy.
DR. HARRINGTON: Dr. Hou, does the literature about hepatic
transplantation contain information about the teratogenic po-
tential of cyclosporin?
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DR. Hou: Three pregnancies have occurred in women with
liver transplants [411. One woman had a therapeutic abortion. A
second had two uncomplicated and successful pregnancies, one
induced by clomiphene. She took azathioprine and prednisone
during both pregnancies.
DR. LEVEY: Until the safety of cyclosporin during pregnancy
is verified, it might be preferable if azathioprine were substitut-
ed for cyclosporin after transplantation in women wishing to
conceive. Experience in several U.S. centers suggests that this
substitution rarely leads to graft rejection after successful
transplantation.
DR. MARY D'ALTON (Department of Maternal-Fetal Medi-
cine, St. Margaret's Hospital for Women, Boston, Mass.):
Would you please comment on the mode of delivery in renal
transplant recipients and on the value of renal echogram during
labor to detect compression of the kidney? Do you think this is
a valid approach?
DR. HAYSLETT: Patients with renal allografts usually experi-
ence no unusual problems with vaginal delivery, because the
kidney lies in the false pelvis. Ultrasound studies could be
important in planning delivery if the anatomic placement of the
kidney was abnormal.
DR. RONALD PERRONE (Division of Nephrology, NEMC):
Why was sodium restricted in this patient from the beginning of
her pregnancy?
DR. HAYSLETT: Patients with heavy proteinuria prior to
pregnancy, as exemplified by this patient, generally experience
increasing edema during gestation. We initiated a low-sodium
diet early in pregnancy to blunt the rate of edema formation.
Because pregnant women conserve sodium normally, we ran no
apparent risk of inducing volume depletion by this measure. We
aim to reduce edema formation in an attempt to provide greater
comfort to the patient, and to reduce the effects of volume
expansion on hypertension.
DR. GELMAN: You alluded to the animal model of pseudo-
pregnancy and said that during this condition sodium balance
and GFR can mimic those of the pregnant state. Can you
explain these most interesting findings?
DR. HAYSLETT: Pseudopregnancy in the rat, produced by
breeding normal females with vasectomized males, is character-
ized by the renal changes and the extrarenal physiologic charac-
teristics of normal pregnancy. This model should provide an
exciting experimental paradigm by which we can explore the
factors that cause the well-known physiologic changes of
pregnancy.
DR. DAVID CAHAN (Chi ef of Nephrology, Faulkner Hospital,
Boston, Mass.): In preeclampsia, are the epithelial foot pro-
cesses well preserved?
DR. HAYSLETT: In preeclampsia the foot processes are not
effaced as in lipoid nephrosis. This finding suggests that the
mechanism of proteinuria involves a loss of size as well as,
possibly, of charge selectivity. I am not aware of any formal
investigations of the mechanism of proteinuria in preeclamptic
women, but methods are available that would make such a
study feasible.
DR. HARRINOTON: How accurate is the DHEA method for
measuring arterial perfusion? My own bias is that it is not a
valid index.
DR. HAYSLETT: The DHEA method is not a direct measure of
placental blood flow, but rather an index of a metabolic function
of the placenta that is thought to correlate with blood flow.
Because of the great concern about the effect of a variety of
therapeutic agents on placental blood flow, and hence on fetal
viability, noninvasive methods that accurately reflect placental
blood flow are urgently needed.
DR. HARRINGTON: Could one examine arterial blood flow in
experimental models of preeclampsia such as that described in
sheep by Ferris?
DR. HAYSLETT: Unfortunately, no experimental model of
toxemia, including the one used by Dr. Ferris in sheep [42],
closely approximates the human syndrome. The lack of an
experimental model of toxemia has created increased difficul-
ties in attempts at unraveling the cause and pathogenesis of
toxemia.
DR. Hou: You mentioned that Feitelson and Lindheimer [351
define moderate hypertension in the third trimester as a diastol-
ic blood pressure of greater than 110 mm Hg. When such a
blood pressure is secondary to preeclampsia, prompt delivery is
often instituted. What are your guidelines for delivering a
pregnant woman with renal disease and worsening
hypertension?
DR. HAYSLETT: In preeclampsia, delivery is an effective
means of controlling accelerated hypertension. When hyperten-
sion is caused by severe renal parenchymal disease, it is not
clear that termination of pregnancy will reduce hypertension.
Because diastolic blood pressures of 110 mm Hg and above are
associated with significant maternal cardiovascular complica-
tions, vigorous efforts should be undertaken to prevent blood
pressure from persisting at that level. This type of intervention
may include therapeutic agents that are potentially harmful to
the fetus. If all measures failed to control accelerated hyperten-
sion, termination of pregnancy would be an acceptable
alternative.
DR. Hou: If a patient's renal function worsens in the absence
of hypertension prior to assumed fetal viability, would you
advise terminating the pregnancy?
DR. HAYSLETF: Because no evidence exists that pregnancy
affects the course of underlying renal disease, except in pre-
eclamptic women, there is usually no reason to interrupt
pregnancy. Attempts should be made to closely monitor fetal
maturity, and delivery should be performed when fetal viability
seems likely.
DR. LEVEY: Why do women hyperventilate during
pregnancy?
DR. HAYSLETT: Women hyperventilate during the latter
stages of pregnancy because the enlarging uterus elevates the
diaphragm. As I mentioned earlier, elevated levels of progester-
one also can contribute to hyperventilation. Detailed evaluation
of this phenomenon has been reported [43].
DR. MCCAULEY: What is the importance of the 30% to 50%
increase in GFR in normal pregnancy? In patients with chronic
glomerulonephritis, and in other states in which intravascular
volume is effectively lower, might one expect to see a difference
in the outcome of pregnancy?
DR. HAYSLETT: The importance of the increase in GFR in
normal pregnancy is, of course, unknown. This change might
simply reflect the generalized decrease in vascular resistance
that characterizes pregnancy. In patients with a chronic reduc-
tion in GFR that is due to renal disease, the small increment in
GFR provides a higher absolute GFR during gestation that
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intuitively might prove advantageous to the patient. A reduc-
tion in GFR to levels below the normal, nonpregnant value has
been associated with fetal growth retardation.
DR. MCCAULEY: Is there an increased risk to the mother or
child if the GFR does not increase during pregnancy?
DR. HAYSLETT: This might be a question that can be ad-
dressed in the rat model of normal pregnancy.
DR. HARRINGTON: Brenner and others have argued that
increased GFR per residual nephron can lead to focal sclerosis.
Does the pseudopregnant rat manifest any changes that mimic
focal sclerosis?
DR. HAYSLETT: I am not aware of studies in which glomeru-
lar histology has been carefully studied after single or consecu-
tive pregnancies in animals or humans. Pregnancy, because of
the remarkable sustained increases in GFR, could provide an
interesting model for examining whether persistent elevations
in glomerular capillary flow lead to glomerular histopathologic
changes.
Reprint requests to Dr. J. P. Haysleit, Department of Medicine, Yale
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